Issuu on Google+

10

This is the 1st study in young children to show a reduced risk of infection following consumption of Aptamil Junior supplemented scGOS/lcFOS (1.2g/100mL) / and omega-3 LCPUFA (19.2mg/100mL)

11

Looking at the total number of infections, there is a tremendous reduction in the occurrence of infections in the Aptamil Junior group

This is the 1st study in healthy children aged 1-3 years to show a bifidogenic effect after 12 weeks of scGOS/lcFOS/ LCPUFA consumption

p=0.724

p=0.004

p=0.002

p<0.005

Looking at the total number of infections, there is a tremendous reduction in the occurrence of infections in the Aptamil Junior group

% Bifidobacteria

60

Nr of subjects

100 80

More children with 0 reported episodes in active group

60

20

Less children with small numbers of reprted episodes in active group 0

40 No difference between groups in percentages of children with high numbers of reported episodes

Aptamil Junior Group

20

Baseline wk 12 Control

Baseline wk 12 Group 1

Baseline wk 12 Group 2

Control Group

0

0

1

2

3

4

5

6

7

8

9

10 11 12 13

14 15

16 17

nr of reported infectious episodes

In the group consuming Aptamil Junior, there is a significant increase in the number of children experiencing no infectious episodes

% of Young Children with 0 infectious episode

40

scGOS/lcFOS: 0.4 g/100 ml (2.5 g) LCPUFA: 3.5 mg / 100 ml 22 mg)

scGOS/lcFOS: 0.4 g/100 ml (2.5 g) LCPUFA: 3.5 mg / 100 ml 22 mg)

scGOS/lcFOS: 0.95 g/100 ml (2.5 g) LCPUFA: 16.4 mg / 100 ml 103 mg)

22 mg/d (2-3 cups)

2.5 g/d 22mg/d (2-3 cups)

6 g/d 103g/d (2-3 cups)

P=0.003

25 20

There is a significant reduction in the total occurrence of infections with Aptamil Junior (p=0.01) group

15 10 5 0 Aptamil Junior Group

Control Group

*P-value based on parents reported infections episodes assessed by investigator RCT, double-blind-controlled, parallel multi country intervention trial, N=767 healthy children (11-29 months) consuming 500 ml of Aptamil Junior randomized into Aptamil Junior Group N= 388; Control Group N=379, receiving GUM without scGOS/lcFOS/n-3 LCPUFA for 52 weeks

Randomized, double-blind, placebo controlled Study, N=195 healthy children (1-3 years old), randomized to 3 groups. Children asked to consume 3 servings of 210 mL of Aptamil Junior for 12 weeks. Faecal samples collected at baseline and at week12.

Aptamil Junior with prebiotics & omega-3 LCPUFAs shows a positive effect on gut microbiota in a healthy population of young children, thus induces a beneficial effect on the immune system


Aptamil